Celltrion
CompanySouth KoreaFounded 1991
Celltrion develops one asset, approved (rosuvastatin). Mostly small molecule acting on lipid and ceramide metabolism, SLC5A2 and HMGCR; based in South Korea, founded in 1991.
- 1
- Asset
- Furthest
- Approved
- 8
- Trials
- 2
- Signals
Pipeline
1HMG-CoA reductase inhibitor lowering LDL cholesterol.
Approved, Small molecule, Lipid and ceramide metabolism, SLC5A2, acute coronary syndrome (Phase 3), atherosclerosis (Phase 3)
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Trials11
- Signals5
- Integrity notices1
- Similar companies6
Updated 9 Oct 2026 · 99 sources